Harwood Feffer LLP Announces Investigation of Galectin Therapeutics Inc.
NEW YORK, July 31, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against Galectin Therapeutics Inc. ("Galectin" or the "Company") (NASDAQ: GALT) and its board of directors concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws.
On July 28 2014, an article was published on a financial blogging website alleging that Galectin had paid stock promoters to pump the Company's stock and future prospects. According to the report, corporate insiders sold millions of dollars in stock during the stock promotion. On July 29, 2014, the Company disclosed poor results in a trial of its liver drug candidate and Galectin stock dropped nearly 60%.
If you own Galectin shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. © 2014 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP